<DOC>
	<DOC>NCT02247141</DOC>
	<brief_summary>The primary objective was to determine the efficacy of Human Normal Immunoglobulin (Subgam®) given subcutaneously by weekly infusion to patients with primary antibody deficiency. The secondary objective was to determine the safety of Subgam® given subcutaneously by weekly infusion to patients with primary antibody deficiency.</brief_summary>
	<brief_title>A Multi-centre Open Study to Assess the Safety and Efficacy of Subgam®</brief_title>
	<detailed_description />
	<mesh_term>Common Variable Immunodeficiency</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>The main criteria for inclusion in the study were as follows: A diagnosis of primary antibody deficiency; No lower or upper age limit (any age was eligible); With stable disease and receiving immunoglobulin (IVIG or SCIG) therapy for at least six months prior to starting the study; Written informed consent (patient/parent/guardian).</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2014</verification_date>
</DOC>